AMSA Combination ChernotheraDvId in Patients with Acute Myelogenous Leukemia Unsuitable for Standard Antileukemic Treatment

References

• Büchner Th., Urbanitz D., Hiddemann W., Rühl H., Ludwig W.-D., Fischer J., Aul H. C., Vaupel H. A., Kuse R., Zeile G., Nowrousian M. R., König H. J., Walter M., Wendt F., Sodomann H., Hossfeld D. K., Von Paleske A., Löffler H., Gassmann W., Hellriegel K. P., Fülle H. H., Lunscken Ch., Emmerich B., Pralle H., Pees H. W., Pfreundschuh M., Bartels H., Koeppen H. M., Schwerdtfeger R., Donhuijsen-Ant R., Mainzer K., Bonfert B., Köppler H., Zurborn K. H., Ranft K., Thiel E., Heinecke A. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J. Clin. Oncol. 1985; 3: 1583–9
   PubMed Web of Science ®Google Scholar
• Cassileth P. A., Begg C. B., Bennett J. M., Bozdech M., Kahn S. B., Weiler C., Glick J. H. A randomized study on the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 1984; 63: 843–7
   PubMed Web of Science ®Google Scholar
• Champlin R., Jacobs A., Gale R. P., Boccia R., Elashoff R., Foon K., Zighelboim J. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy. Lancet 1984; 1: 894–6
   PubMed Web of Science ®Google Scholar
• Gale R. P., Cline M. J. High remission-induction rate in acute myeloid leukaemia. Lunrer 1977; I: 497–9
   Google Scholar
• Glucksberg H., Cheever M. A., Farewell V. T., Fefer A., Sale G. E., Thomas E. D. High-dose combination chemotherapy for acute non lymphoblastic leukemia in adults. Cancer 1981; 48: 1073–81
   PubMed Web of Science ®Google Scholar
• Hayat M., Jehn U., Willemze R., Haanen C., Zittoun R., Monconduit M., Lowenberg B., Stryckmans P., Peetermans M., De Cataldo F., Kerkhofs H., Abels J., Klein H. O., Andrien J., Goudsmit R., Cauchie C., Suciu S., Solbu G. A. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult myelogenous leukemia. A leukemia-lymphoma group trial of the EORTC. Cuncer 1986; 58: 617–23
   PubMed Web of Science ®Google Scholar
• Preisler H., Davis R. B., Kirshner J., Dupre E., Richards F., III, Hoagland C., Kopel S., Levy R. N., Carey R., Schulman P., Gottlieb A. J., McIntyre R. Comparison of thrcc remission induction regimens and two post induction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study. Blood 1987; 69: 1441–9, the Cancer and Leukemia Group B.
   PubMed Web of Science ®Google Scholar
• Rai K. R., Holland J. K., Glidewell O. J., Weinberg V., Brunner K., Obrecht J. P., Preisler H. D., Nawabi I. W., Prager D., Carey R. W., Cooper M. R., Haurani F., Hutchinson J. L., Silver R. T., Falkson G., Wiernik P., Hoagland H. C., Bloomfield C. D., James G. W., Gottlieb A., Ramanan S. V., Blom J., Nissen N. I., Bank A., Ellison R. R., Kung F., Henry P., McIntyre O. R., Kaan S. K. Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood 1981; 58: 1203–12
   PubMed Web of Science ®Google Scholar
• Rees J. K. H., Gray R. G., Swirsky D., Hayhoe F. G. J. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 11: 1236–41
   Google Scholar
• Sauter C., Berchtold W., Fopp M., Imbach P., Tschopp L., Gratwohl A., Maurice P., Von Fliedner V., Cavalli F. Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1984; i: 379–82
   Google Scholar
• Vogler W. R., Winton E. F., Gordon D. S., Raney M. R., Go B., Meyer L. A randomized comparison of postremission therapy in acute myelogenous leukemia: A Southeastern Cancer Study Group trial. Blood 1984; 63: 1039–45
   PubMed Web of Science ®Google Scholar
• Walters R. S., Kantarjian H. M., Keating M. J., Estey E. H., McCredie K. B., Freireich E. J. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 1987; 60: 149–55
   PubMed Web of Science ®Google Scholar
• Capizzi R. L., Poole M., Cooper M. R., Richards Ii F., Stuart J. J., Jackson D. V., Jr., White D. R., Spurr C. L., Hopkins J. A., Muss H. B., Rudnick S. A., Wells R., Gabriel D., Ross D. Treatment of poor risk acute leukemia with sequential high-dose ara-C and asparaginase. Blood 1984; 63: 694–700
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Kreutzmann H., Straif K., Ludwig W.-D., Mertelsmann R., Donhuijsen-Ant R., Lengfelder E., Arlin Z., Büchner T. High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744–9
   PubMed Web of Science ®Google Scholar
• Arlin Z. A., Flomenberg N., Gee T. S., Kempin S. J., Dellaquilla C., Mertelsmann R., Straus D. J., Young C. W., Clarkson B. D. Treatment of acute leukemia in relapse with 4′-(9′-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine. Cancer Clin. Trials 1981; 4: 317–21
   PubMedGoogle Scholar
• Arlin Z. A., Ahmed T. A., Mittelman A., Feldman E., Mehta R., Weinstein P., Rieber E., Sullivan P., Baskind P. A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. J. Clin. Oncol. 1987; 5: 371–5
   PubMed Web of Science ®Google Scholar
• Boccia R., Zighelboim J., Champlin R. E., Kim C. C., Gale R. P. AMSA: A phase II trial in resistant and recurrent acute myelogenous leukemia. Med. Ped. Oncol. 1984; 12: 178–9
   PubMedGoogle Scholar
• Hines J. D., Oken M. M., Mazza J. J., Keller A. M., Streeter R. R., Glick J. H. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute non-lymphocytic leukemia. J. Clin. Oncol. 1984; 2: 545–9
   PubMed Web of Science ®Google Scholar
• Legha S. S., Keating M. J., McCredie K. B., Bodey G. P., Freireich E. J. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. Blood 1982; 60: 484–90
   PubMed Web of Science ®Google Scholar
• Louie A. C., Issell B. F. Amsacrine (AMSA)—A clinical review. J. Clin. Oncol. 1985; 3: 562–593
   PubMed Web of Science ®Google Scholar
• Zittoun R., Bury J., Stryckmans P., Lowenberg B., Rozendaal K. Y., Haanen C., Kerkhofs M., Jehn U., Willemze R. Amsacrine with high-dose cytarabine in acute leukemia. Cancer Treat. Rep. 1985; 69: 1447–8
   PubMedGoogle Scholar
• Weiss R. B., Grillo-López A. J., Marsoni S., Posada J. G., Jr., Hess F., Ross B. J. Amsacrine-associated cardiotoxicity: An analysis of 82 cases. J. Clin. Oncol. 1986; 4: 918–28
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukaemias: French-American-British (FAB) Co-operative Group. Br. J. Haematol. 1976; 33: 451–58
   PubMed Web of Science ®Google Scholar
• Neame P. B., Soamboonsrup P., Browman G. P., Meyer R. M., Benger A., Wilson W. E. C., Walker I. R., Saeed N., McBride J. A. Classifying acute leukemia by immunophenotyping: A combined FAB-immunologic classification of AML. Blood 1986; 68: 1355–62
   PubMed Web of Science ®Google Scholar
• Mufti G. J., Oscier D. G., Hamblin T. J., Bell A. J. Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. N. Engl. J. Med. 1983; 309: 1653–4
   PubMed Web of Science ®Google Scholar
• Winter J. N., Variakojis D., Gaynor E. R., Larson R. A., Miller K. B. Low-dose cytosine arabinoside (ara-c) therapy in the myelodysplastic syndromes and acute leukemia. Cancer 1985; 56: 443–9
   PubMed Web of Science ®Google Scholar
• Wiernik P. H., Serpick A. A. Factors effecting remission and survival in adult acute nonlymphocytic leukemia (ANLL). Medicine 1970; 49: 505–13
   PubMed Web of Science ®Google Scholar
• Mittelman A., Arlin Z. A. AMSA-induced seizures in patients with hypokalemia. Cancer Treat. Rep. 1983; 67: 102–3
   PubMedGoogle Scholar